CHMP Highlights: No For Xyndari, Edaravone MAA Pulled And Good News For Univar’s Cufence

This month’s meeting of the European Medicines Agency’s CHMP appears to have been eventful. One marketing authorization application was rejected, one was pulled, and an earlier negative opinion was upheld. Four MAAs were recommended for approval, including a new treatment from Univar for Wilson’s disease.